Literature DB >> 28741095

Phenotype microarray analysis of the AdeRS two-component system in Acinetobacter baumannii.

J-R Sun1, Y-S Chiang2,3, H-S Shang1, C-L Perng1,2, Y-S Yang4, T-S Chiueh5.   

Abstract

Acinetobacter baumannii is a nosocomial pathogen capable of resistance to multiple antimicrobials. The AdeRS two-component system (TCS) is associated with antimicrobial resistance by controlling the AdeABC efflux pump. To elucidate modulation by AdeRS, we made an A. baumannii mutant lacking the AdeRS TCS and characterized it using phenotype microarray (PM) analysis. After disrupting the adeRS operon, lower expression of AdeABC efflux pump was observed in the mutant strain. PM analysis showed that the AdeRS deletion strain and parental strain presented different tolerances to 91 compounds. Tolerance to 54 of the 91 compounds could be restored by complementing the AdeRS deleted strain with a plasmid carrying the adeRS gene. Compared to the parental strain, the AdeRS deletion strain was more sensitive to various inhibitors that target on-protein synthesis and function of cell membrane permeability. Tolerance to phleomycin of the AdeRS deletion strain reduced greatly and was further confirmed with minimum inhibitory concentration (MIC) determination and spot assay. The efflux pump inhibitor, NMP, could reduce phleomycin MIC four-fold at least for 29 (34.8%) of 81 tigecycline-resistant extensively drug-resistant A. baumannii (TGC-resistant XDRAB) clinical isolates. Our results suggested that the AdeRS TCS of A. baumannii was important for both elimination of antibiotics and tolerance to particular compounds.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28741095     DOI: 10.1007/s10096-017-3066-9

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN: 0934-9723            Impact factor:   3.267


  36 in total

1.  In vitro reduction of antibacterial activity of tigecycline against multidrug-resistant Acinetobacter baumannii with host stress hormone norepinephrine.

Authors:  Masato Inaba; Naoyuki Matsuda; Hirotsugu Banno; Wanchun Jin; Jun-Ichi Wachino; Keiko Yamada; Kouji Kimura; Yoshichika Arakawa
Journal:  Int J Antimicrob Agents       Date:  2016-11-04       Impact factor: 5.283

2.  Diversity of polymyxin resistance mechanisms among Acinetobacter baumannii clinical isolates.

Authors:  Raquel Girardello; Marina Visconde; Rodrigo Cayô; Regina Célia Bressan Queiroz de Figueiredo; Marcelo Alves da Silva Mori; Nilton Lincopan; Ana Cristina Gales
Journal:  Diagn Microbiol Infect Dis       Date:  2016-10-08       Impact factor: 2.803

3.  RND-type efflux pumps in multidrug-resistant clinical isolates of Acinetobacter baumannii: major role for AdeABC overexpression and AdeRS mutations.

Authors:  Eun-Jeong Yoon; Patrice Courvalin; Catherine Grillot-Courvalin
Journal:  Antimicrob Agents Chemother       Date:  2013-04-15       Impact factor: 5.191

4.  Molecular epidemiology and mechanisms of tigecycline resistance in clinical isolates of Acinetobacter baumannii from a Chinese university hospital.

Authors:  Mei Deng; Man-Hua Zhu; Jun-Jie Li; Sheng Bi; Zi-Ke Sheng; Fei-Shu Hu; Jia-Jie Zhang; Wei Chen; Xiao-Wei Xue; Ji-Fang Sheng; Lan-Juan Li
Journal:  Antimicrob Agents Chemother       Date:  2013-10-28       Impact factor: 5.191

5.  The Pseudomonas aeruginosa periplasmic protease CtpA can affect systems that impact its ability to mount both acute and chronic infections.

Authors:  Jin Seo; Andrew J Darwin
Journal:  Infect Immun       Date:  2013-09-30       Impact factor: 3.441

6.  Rapid multiplexed phenotypic screening identifies drug resistance functions for three novel efflux pumps in Acinetobacter baumannii.

Authors:  Liping Li; Karl A Hassan; Melissa H Brown; Ian T Paulsen
Journal:  J Antimicrob Chemother       Date:  2016-01-31       Impact factor: 5.790

7.  A truncated AdeS kinase protein generated by ISAba1 insertion correlates with tigecycline resistance in Acinetobacter baumannii.

Authors:  Jun-Ren Sun; Cherng-Lih Perng; Ming-Chin Chan; Yuji Morita; Jung-Chung Lin; Chih-Mao Su; Wei-Yao Wang; Tein-Yao Chang; Tzong-Shi Chiueh
Journal:  PLoS One       Date:  2012-11-14       Impact factor: 3.240

8.  Contribution of resistance-nodulation-cell division efflux systems to antibiotic resistance and biofilm formation in Acinetobacter baumannii.

Authors:  Eun-Jeong Yoon; Yassine Nait Chabane; Sylvie Goussard; Erik Snesrud; Patrice Courvalin; Emmanuelle Dé; Catherine Grillot-Courvalin
Journal:  MBio       Date:  2015-03-24       Impact factor: 7.867

9.  The Role of the Two-Component System BaeSR in Disposing Chemicals through Regulating Transporter Systems in Acinetobacter baumannii.

Authors:  Ming-Feng Lin; Yun-You Lin; Chung-Yu Lan
Journal:  PLoS One       Date:  2015-07-10       Impact factor: 3.240

10.  Contribution of the Ade Resistance-Nodulation-Cell Division-Type Efflux Pumps to Fitness and Pathogenesis of Acinetobacter baumannii.

Authors:  Eun-Jeong Yoon; Viviane Balloy; Laurence Fiette; Michel Chignard; Patrice Courvalin; Catherine Grillot-Courvalin
Journal:  mBio       Date:  2016-05-31       Impact factor: 7.867

View more
  3 in total

Review 1.  Bacterial Multidrug Efflux Pumps at the Frontline of Antimicrobial Resistance: An Overview.

Authors:  Lulu Huang; Cuirong Wu; Haijiao Gao; Chao Xu; Menghong Dai; Lingli Huang; Haihong Hao; Xu Wang; Guyue Cheng
Journal:  Antibiotics (Basel)       Date:  2022-04-13

2.  Analysis of multidrug resistance in Streptococcus suis ATCC 700794 under tylosin stress.

Authors:  Rui-Xiang Che; Xiao-Xu Xing; Xin Liu; Qian-Wei Qu; Mo Chen; Fei Yu; Jin-Xin Ma; Xing-Ru Chen; Yong-Hui Zhou; Bello-Onaghise God'Spower; Ji-Wen Liu; Zhao-Xiang Lu; Ya-Ping Xu; Yan-Hua Li
Journal:  Virulence       Date:  2019-12       Impact factor: 5.882

3.  Ser253Leu substitution in PmrB contributes to colistin resistance in clinical Acinetobacter nosocomialis.

Authors:  Ya-Sung Yang; Wen-Yih Jeng; Yi-Tzu Lee; Chi-Ju Hsu; Yu-Ching Chou; Shu-Chen Kuo; Cheng-Cheung Chen; Wei-Jane Hsu; Hsing-Yu Chen; Jun-Ren Sun
Journal:  Emerg Microbes Infect       Date:  2021-12       Impact factor: 7.163

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.